Sign In
Buy AFCG
AFC Gamma Earnings Calls
| Release date | Aug 13, 2026 |
| EPS estimate | $0.200 |
| EPS actual | - |
| Revenue estimate | 8.643M |
| Revenue actual | - |
| Expected change | +/- 8.45% |
| Release date | May 07, 2026 |
| EPS estimate | $0.160 |
| EPS actual | $0.210 |
| EPS Surprise | 31.25% |
| Revenue estimate | 6.899M |
| Revenue actual | 9.813M |
| Revenue Surprise | 42.24% |
| Release date | Mar 04, 2026 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.120 |
| EPS Surprise | -200.00% |
| Revenue estimate | 5.58M |
| Revenue actual | 5.186M |
| Revenue Surprise | -7.05% |
| Release date | Nov 12, 2025 |
| EPS estimate | $0.190 |
| EPS actual | $0.160 |
| EPS Surprise | -15.79% |
| Revenue estimate | 5.357M |
| Revenue actual | -841830 |
| Revenue Surprise | -115.71% |
Last 4 Quarters for AFC Gamma
Below you can see how AFCG performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Nov 12, 2025 |
| Price on release | $3.26 |
| EPS estimate | $0.190 |
| EPS actual | $0.160 |
| EPS surprise | -15.79% |
| Date | Price |
|---|---|
| Nov 06, 2025 | $3.08 |
| Nov 07, 2025 | $3.12 |
| Nov 10, 2025 | $3.13 |
| Nov 11, 2025 | $3.24 |
| Nov 12, 2025 | $3.26 |
| Nov 13, 2025 | $3.10 |
| Nov 14, 2025 | $3.13 |
| Nov 17, 2025 | $3.02 |
| Nov 18, 2025 | $2.82 |
| 4 days before | 5.84% |
| 4 days after | -13.50% |
| On release day | -4.91% |
| Change in period | -8.44% |
| Release date | Mar 04, 2026 |
| Price on release | $2.41 |
| EPS estimate | -$0.0400 |
| EPS actual | -$0.120 |
| EPS surprise | -200.00% |
| Date | Price |
|---|---|
| Feb 26, 2026 | $2.38 |
| Feb 27, 2026 | $2.28 |
| Mar 02, 2026 | $2.32 |
| Mar 03, 2026 | $2.21 |
| Mar 04, 2026 | $2.41 |
| Mar 05, 2026 | $2.57 |
| Mar 06, 2026 | $2.62 |
| Mar 09, 2026 | $2.57 |
| Mar 10, 2026 | $2.64 |
| 4 days before | 1.26% |
| 4 days after | 9.54% |
| On release day | 6.64% |
| Change in period | 10.92% |
| Release date | May 07, 2026 |
| Price on release | $3.09 |
| EPS estimate | $0.160 |
| EPS actual | $0.210 |
| EPS surprise | 31.25% |
| Date | Price |
|---|---|
| May 01, 2026 | $2.90 |
| May 04, 2026 | $2.93 |
| May 05, 2026 | $2.85 |
| May 06, 2026 | $2.77 |
| May 07, 2026 | $3.09 |
| May 08, 2026 | $3.22 |
| May 11, 2026 | $3.23 |
| May 12, 2026 | $3.26 |
| May 13, 2026 | $2.96 |
| 4 days before | 6.55% |
| 4 days after | -4.21% |
| On release day | 4.21% |
| Change in period | 2.07% |
| Release date | Aug 13, 2026 |
| Price on release | - |
| EPS estimate | $0.200 |
| EPS actual | - |
| Date | Price |
|---|---|
| Jul 06, 2026 | $3.02 |
| Jul 07, 2026 | $2.97 |
| Jul 08, 2026 | $2.96 |
| Jul 09, 2026 | $2.92 |
| Jul 10, 2026 | $2.87 |
AFC Gamma Earnings Call Transcript Summary of Q1 2026
Advanced Flower Capital completed its conversion to a BDC in Q1 2026 and is actively expanding beyond cannabis into lower middle market private credit. The company closed two non-cannabis deals in Q1 totaling ~$90 million and funded an additional $5 million subsequent to quarter-end; net fundings for the quarter were $39.1 million. The firm received $41.2 million in cannabis loan repayments and currently has three loans on non-accrual (including Debbie Holdings, which has produced $20.8 million of paydowns since receivership, and Justice Grown, which is in maturity default and for which the company intends to pursue remedies). Financially, Q1 total investment income was $9.8 million and net investment income was $4.8 million, or $0.21 per basic share. The Board declared and paid a $0.05 per share distribution and authorized a $5 million share buyback program. NAV per share rose to $7.90, up $0.44 from the prior quarter, driven by NII and unrealized appreciation. The company expanded its senior secured revolving credit facility to $80 million (expandable to $100 million) and reported $356.6 million of principal outstanding across 15 loans as of 3/31/2026 (and $370 million across 17 loans as of 5/1/2026). Management emphasizes a strategic focus on the $5M–$50M EBITDA lower middle market, citing improved risk-adjusted returns and a strong pipeline (~$1.5 billion) while remaining selective and disciplined in underwriting.
